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Whole genome sequencing reveals the
emergence of a Pseudomonas aeruginosa
shared strain sub-lineage among patients
treated within a single cystic fibrosis centre
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Kay A. Ramsay2,5, Iain Lamont8, David M. Whiley9,10, Scott C. Bell2,3,5,11 and Scott A. Beatson1,11,12*
Abstract
Background: Chronic lung infections caused by Pseudomonas aeruginosa are a significant cause of morbidity and
mortality in people with cystic fibrosis (CF). Shared P. aeruginosa strains, that can be transmitted between patients,
are of concern and in Australia the AUST-02 shared strain is predominant in individuals attending CF centres in
Queensland and Western Australia. M3L7 is a multidrug resistant sub-type of AUST-02 that was recently identified in
a Queensland CF centre and was shown to be associated with poorer clinical outcomes. The main aim of this study
was to resolve the relationship of the emergent M3L7 sub-type within the AUST-02 group of strains using whole
genome sequencing.
Results: A whole genome core phylogeny of 63 isolates indicated that M3L7 is a monophyletic sub-lineage within
the context of the broader AUST-02 group. Relatively short branch lengths connected all of the M3L7 isolates. A
phylogeny based on nucleotide polymorphisms present across the genome showed that the chronological
estimation of the most recent common ancestor was around 2001 (± 3 years). SNP differences between sequential
non-hypermutator M3L7 isolates collected 3–4 years apart from five patients suggested both continuous infection
of the same strain and cross-infection of some M3L7 variants between patients. The majority of polymorphisms that
were characteristic of M3L7 (i.e. acquired after divergence from all other AUST-02 isolates sequenced) were found
to produce non-synonymous mutations in virulence and antibiotic resistance genes.
Conclusions: M3L7 has recently diverged from a common ancestor, indicating descent from a single carrier at a CF
treatment centre in Australia. Both adaptation to the lung and transmission of M3L7 between adults attending this
centre may have contributed to its rapid dissemination. Further genomic investigations are required on multiple
intra-sample isolates of this sub-type to decipher potential mechanisms which facilitates its epidemiological success.
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Background
Cystic fibrosis (CF) is the most common recessively lethal
inherited disease in people of European ancestry. The
majority of mortality and morbidity in people with CF
is caused by chronic lung infection with Pseudomonas
aeruginosa [1]. During chronic infections P. aeruginosa
adapts to the CF airway microenvironment, which pro-
motes multiple phenotypic and genotypic changes including
enhanced resistance to antibiotics, excessive exopolysac-
charide production, auxotrophy, auxotrophic metabolism,
hypermutability and the loss of motility [2–8]. This evolu-
tion strategy has been found to occur in parallel in different
P. aeruginosa strains, suggesting that these pathoadaptive
modifications are important in the transition from an
opportunistic pathogen to a specialised pathogen of diseased
human lungs [8].
Person-to-person transmission of airway-adapted P.
aeruginosa strains has also been reported with the
acquisition of some “shared strains” (also referred to as
“epidemic” or “transmissible” strains) correlated with
adverse clinical outcomes [9–13]. AUST-02 (Sequence
Type [ST] 775) is a prevalent shared strain in CF
centres around Australia and is the dominant strain in
Queensland infecting approximately 40% of patients
infected with P. aeruginosa [10, 14, 15]. A recent study
further demonstrated that ongoing evolution within
this clonally successful AUST-02 strain has led to the
emergence and dissemination of a sub-type within a
treatment centre (Brisbane, Queensland) which infected
approximately 5% of patients [16]. This sub-type could
be distinguished from all other AUST-02 sub-types by a
unique mexZ (mexZ-3, M3) and lasR (lasR-7, L7) genotype
and therefore, was designated M3L7 [16]. The M3L7
sub-type is of particular clinical importance given that
it is associated with enhanced multidrug resistance,
transmissibility, greater intravenous antibiotic and hospi-
talisation requirements, and a higher 3-year risk of death/
lung transplantation, than other AUST-02 subtypes [16].
Whole genome sequencing (WGS) of 11 longitudinal
M3L7 isolates from a single patient revealed the within-
host diversity of M3L7 during and after antibiotic treat-
ment of an acute pulmonary exacerbation in 2014 [17],
but the M3L7 sub-type has yet to be characterised at the
population level.
The aim of this study was to use WGS to reconstruct
the population structure and resolve the relationship of
the M3L7 sub-type within the AUST-02 group of strains.
The analyses revealed that the M3L7 sub-type has
recently diverged from a common ancestor, suggesting
descent from a single founder within a rapidly growing
CF centre population. Genetic mutations exclusive to
the M3L7 sub-type were identified and may have aided
adaptation to the CF airway microenvironment prior to
its dissemination.
Methods
Selection of bacterial isolates
One to three P. aeruginosa isolates were cultured from sin-
gle sputum specimens (collected annually in 2007, 2008 and
2011) from adults with CF attending The Prince Charles
Hospital as per the Australian Clonal P. aeruginosa in Cystic
Fibrosis (ACPinCF) study protocol [10]. In brief, sputum
samples were prospectively collected and when P. aerugi-
nosa was identified, three colonies representing different
morphotypes from each specimen were randomly selected.
Cross-sectional molecular surveillance for the M3L7 sub-
type was conducted in P. aeruginosa isolates collected from
study participants at two time-points (2007–2008 and
2011). The M3L7 sub-type was detected in 28/509 (5.5%) P.
aeruginosa isolates collected from 13/170 (7.6%) patients in
2007–2008 and in 21/519 (4.0%) P. aeruginosa isolates from
11/173 (6.4%) patients in 2011 [16]. Twenty-five of these
M3L7 isolates (named AUS934 to AUS958) were selected
from 19 patients (patients 24 to 42; Additional file 1:
Table S1) for further WGS as described below.
Of the 13 patients identified with M3L7 in 2007–2008,
six patients had no follow-up isolates available (five under-
went lung transplantation and one moved interstate by
2011; Patients 24, 32, 33, 34, 35 and 36). Of the seven
patients who had M3L7 infection in 2007–2008 and had
samples collected in 2011, five remained infected with
M3L7 in 2011 (Patients 28, 30, 31, 38 and 41), one
(Patient 37) no longer had the M3L7 sub-type detected,
while another (Patient 39) tested positive by the M3
allele-specific PCR, but the lasR sequence could not be
determined because of suboptimal sequence quality (this
isolate, AUS947, was subsequently confirmed as M3L7 by
WGS in this study). A further five patients (Patients 25, 26,
27, 40 and 42) acquired M3L7 in 2011 (they were infected
with other strains in 2007) and were identified as incident
cases. Finally, one patient (Patient 29) infected with M3L7
in 2011 had no previous strain-typing data available [16].
One M3L7 isolate was randomly selected per patient at
each time-point (2007–2008 and 2011) for WGS and com-
prised: i) 13 M3L7 isolates from 13 patients in 2007–2008;
ii) six M3L7 isolates from six patients with persistent
M3L7 infection in 2011; iii) five M3L7 isolates from five
incident cases in 2011; and iv) one M3L7 isolate from a
patient with no previous P. aeruginosa strain typing
data collected in 2011. One further P. aeruginosa isolate
(AUS970) from a patient (patient 43; Additional file 1:
Table S1) in 2007 which contained the M3 mexZ allele
and a non-L7 lasR genotype was included as an outgroup.
These patients had chronic infection with P. aeruginosa
prior to 2007 [18, 19].
Whole genome sequencing
Preparation of genomic DNA for WGS was undertaken
using the UltraClean® Microbial DNA Isolation Kit as
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described previously [17]. Library preparation (Truseq),
qPCR (TapeStation, Agilent Genomics) and WGS using
the Illumina HiSeq 2500 platform with 100 bp paired-end
read chemistry were carried out by the Australian Genome
Research Facility, Melbourne, Australia.
In order to reconstruct the M3L7 population structure,
a further 37 AUST-02 genomes that were previously
sequenced (as part of an ongoing AUST-02 population
genetic diversity study (Hanks et al., unpublished)) and a
further 11 M3L7 genomes that were previously sequenced
(as part of a longitudinal study of patient 37 isolates
[17]) were included in the analyses (Additional file 1:
Table S1).
Genome mapping and assembly
Reads were taxonomically assigned with Kraken (v0.10.4)
to check for contamination and trimmed using Nesoni clip
(v0.128) to filter out adapter sequences and low-quality
regions [20, 21]. Reads were mapped to the P. aeruginosa
PAO1 reference genome (NC_002516) using SHRiMP as
implemented in Nesoni (v0.128) [20, 22, 23]. The PAO1
genome was chosen as a reference due to its high quality,
and expert-curated annotation [23]. SNPs and small inser-
tions or deletions (indels) shorter than the read length were
called using Nesoni.
Genomes were assembled using Velvet (v1.2.10) and
VelvetOptimiser (v2.2.5) [24, 25]. Assembled contigs
were reordered against PAO1 using Mauve (v2.4.0) and
annotated with Prokka (v1.10) [26, 27]. Gene annotations
from PAO1 were used as the primary reference. M3L7
and M3L1 draft genome assemblies ranged in total size
from 6.15 to 6.25 Mb (mean = 6.24 Mb) with N50 values
between 226 Kb and 413 Kb (mean = 319Kb).
Phylogenetic analysis
An alignment of 30,811 core SNPs obtained from mapping
against PAO1 was used to reconstruct the phylogeny of
the 63 AUST-02 genome sequences. RAxML (v8.1.15) was
used to estimate the Maximum Likelihood tree with the
rapid bootstrap analysis option (−f a) and GTRGAMMA
model of nucleotide substitution with a correction for
ascertainment bias (−m ASC_GTRGAMMA --asc--
corr lewis) [28]. A resolved phylogeny of all available
M3L7 genome sequences (including the 25 generated in
this study, AUS22 (Hanks et al., unpublished) and the 11
isolates from patient 37 in 2014 [17]) was constructed
from a SNP matrix of 2573 SNPs with the same settings
as above. Phylogenetic trees were viewed and explored
using Dendroscope (v3.4.1) and FigTree (v1.4.2) [29, 30].
Minimum spanning trees using the same SNP matrix were
generated using the goeBURST Full MST algorithm in
Phyloviz using [31].
BEAST analysis
To determine the emergence of the M3L7 sub-type,
Bayesian inference of the evolutionary rates was conducted
using BEAST 1.8.2 [32]. As input a set of 183 SNPs specific
for M3L7 was used, excluding two hypermutator isolates
(AUS937 and AUS938) and the AUS970 outgroup (non-
M3L7 isolate). Regions of clustered SNPs, where at least
three SNPs were found within 10 bp of each other, were
also removed. Among the different combinations of the
molecular clock model (strict and constant relaxed lognor-
mal), substitution model (HKY, GTR) and population size
change (coalescent constant and exponential growth)
models, the preferred combination of parameters selected
based on stepping stone sampling was strict molecular
clock, HKY substitution model with four discrete gamma-
distributed rate categories, and exponential population
size change. Markov Chain Monte Carlo generations were
run in triplicate for 50 million steps, sampling every
5000 steps, to ensure convergence and an ESS value >
200 for all parameters. Replicate runs were combined
using LogCombiner with a 10% burn-in and maximum
credibility trees reporting mean values were created using
TreeAnnotator.
Comparative genomic analyses
Comparative genomic analyses were performed using
Parsnp, Gingr, BRIG (BLAST Ring Image Generator),
Roary (v3.4.2), ACT (Artemis Comparison Tool) and
BLAST [33–36]. Large genomic differences were inves-
tigated using PHAST (PHAge Search Tool) and Roary
[35, 37]. The effect of amino acid substitutions (function-
ally important or no change) were predicted in silico using
PROVEAN (Protein Variation Effect Analyzer) [38].
ABRicate was used to determine acquired resistance
gene content by comparing against the ResFinder and
CARD database [39]. Multi locus sequence typing (MLST)
was performed using the ariba tool and made use of the
PubMLST database [40, 41].
Results and discussion
M3L7 is a distinct sub-lineage of the AUST-02 shared
strain
On the basis of the whole-genome core phylogeny, the
63 AUST-02 isolates form two major discrete lineages
(clades), M2 (n = 34) and M3 (n = 29), consistent with
their possession of mexZ-2 (codon substitution, A38T)
or mexZ-3 (codon substitution, T12N) alleles, respectively
(Fig. 1 and Additional file 2: Figure S1). The M3L7
isolates (n = 26; including 25 isolates sequenced here
and a previously sequenced AUST-02 genome, AUS22
[Patient 32; 2007]) form a monophyletic sub-lineage of
AUST-02 within the M3 clade that has diverged from
all other AUST-02 isolates sequenced to date (Fig. 1).
Three isolates (AUS853 [Patient 45; 2007]; AUS854 [Patient
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44; 2007]; AUS970 [Patient 43; 2007]) within the M3 clade
form deep-branching relationships at the base of the lineage
and do not harbour the lasR-7 allele (L7: 1 bp deletion,
438delG) that defines the M3L7 sub-type. Of the available
AUST-02 sequences, isolate AUS970 [Patient 43; 2007],
sequenced in this study, represented the AUST-02 genome
that was most closely related to the M3L7 sub-lineage.
In addition to the mexZ-3 allele (M3), AUS970 carried
a wild-type lasR-1 (L1) allele (therefore named M3L1).
All 63 isolates are ST-775 according to in silico MLST.
M3L7 diverged recently from other AUST-02 shared
strains
The M3L7 sub-lineage expanded recently following a long
period of divergence from the M2 sub-lineage according to
the relatively short branch lengths connecting the M3L7
isolates and their relative distance from the root (Fig. 1).
Using BEAST analysis (Fig. 2), we estimated that the most
recent common ancestor (MRCA) of M3L7 emerged
around 2001 (± 3 years). This is approximately 6 years
prior to the first isolation of an M3L7 sub-type (2007) in
people with CF in Brisbane (Additional file 3: Figure S2)
[16]. Of note, this time period also corresponds with a
relatively high annual increase (approximately 10–15%)
in the adult CF population at The Prince Charles Hospital
(Additional file 3: Figure S2). This situation, combined
with limited capacity to segregate all patients, particularly
when admitted to an inpatient ward, may have contrib-
uted to shared-strain infections.
The phylogenetic relatedness of M3L7 isolates collected
from multiple unrelated patients (including Patients 30,
31, 36, 37, 39, 40, 41) (Additional file 2; Figure S1), also
supports the hypothesis of cross-infection. Examination of
hospital admission data showed these patients had over-
lapping periods of hospitalisation to the same inpatient
ward at a time when M3L7 was first detected in 2007
(Additional file 4: Table S2). As highlighted previously
[16], molecular surveillance showed a striking absence
of M3L7 amongst P. aeruginosa isolates collected from
patients admitted to other wards during the same period.
This is emphasised by the lack of concurrent methicillin-
resistant Staphylococcus aureus or Burkholderia cepacia
complex infection in those infected with M3L7, which
is most likely due to patients with the former two
infections receiving treatment in alternate inpatient
wards. Baseline sputum samples of four patients with
M3L7 infection, included in this study, had additional
pathogens identified: Achromobacter xylosoxidans (n= 3);
methicillin-susceptible Staphylococcus aureus (n = 2); Myco-
bacterium abscessus (n= 1). In the year prior to recruitment,
Fig. 1 Radial phylogeny of the AUST-02 genomes. The relationship of the M3L7 sub-lineage to other sequenced AUST-02 genomes from patients
attending CF centres in Brisbane/Queensland (Red), Perth/Western Australia (Green) and Sydney/New South Wales (Blue: AUS853, AUS854) is
shown. The M3 outgroup (AUS970, M3L1) is indicated. The major clades (M2 and M3) are represented by pink and yellow shaded boxes and are
defined by different mexZ alleles (M2, A38T; M3, T12N). The scale bar represents 10 nucleotide substitutions. Phylogeny was reconstructed
estimated from an alignment of 30,811 core genome SNPs (relative to PAO1) using RAxML
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a range of co-pathogens were also identified (Additional
file 5: Table S3).
The admission data, combined with WGS data, raises
the possibility of cross-infection of M3L7 within the
inpatient setting. Taken together, these results support a
single founder scenario in which a carrier of the M3L7
sub-type acted as a donor within a CF centre with subse-
quent rapid dissemination in the resident CF population.
Alternatively, dissemination of the M3L7 sub-type may
have arisen through exposure to common environmental
sources; though this is unlikely as earlier surveys of both
hospital and natural environmental sites have failed to
reveal any common sources of shared CF strains [42–44].
Notably, both sub-lineages of AUST-02 are prevalent in
Queensland, suggesting that their MRCA originated in this
state; however, we cannot rule out independent introduc-
tions of M3L7 and M2 founders into the local CF popula-
tion from outside the same geographical region (state).
Resolving the within-patient relationships of M3L7
provides evidence for both continuous infection and
person-to-person transmission
To investigate genomic evidence for continuous infec-
tion within patients and person-to-person transmission,
we examined the pattern of SNP differences between
isolates in more detail. As described previously, the dataset
included six pairs of M3L7 isolates (Additional file 2:
Figure S1) collected from people with CF at two time-
points in 2007 or 2008 and in 2011 [16].
A pair of M3L7 isolates (AUS937 and AUS938) from
patient 38 had accumulated a much higher number of SNPs
compared to other M3L7 isolates, as indicated by their
relatively longer branches in the phylogeny (Additional
file 2: Figure S1). Further analysis revealed that these two
isolates had acquired independent non-synonymous muta-
tions within the mutS gene (AUS937, L341P; AUS938,
1 bp deletion [1076delC]), encoding a DNA mismatch
repair protein [45], and were predicted to be deleterious
to protein function based on an in silico analysis [38].
Mutations in mutS are associated with hypermutation,
which frequently occurs during chronic P. aeruginosa
infection of the CF airway [46, 47]. Notably, hypermuta-
tors were also identified and characterised in longitudinal
isolates collected in 2014 from the person known as
patient 37 in the present study [17]. The 2007 M3L7
isolate (AUS951) is closest to AUS961 from the 2014 M3L7
isolates (Additional file 6: Figure S3), with 14 core SNP
differences according to a minimal spanning tree of pairwise
Fig. 2 Time-calibrated phylogeny of the M3L7 sub-lineage. Ancestral reconstruction was performed using BEAST 1.8.2 based on a 183 bp
non-recombinant SNPs alignment for the 23 non-hypermutator M3L7 strains (sequenced in the current study) isolated between 2007 and
2011, with HKY substitution-, strict clock-, and exponential population tree- models preferred. Posterior probability support is indicated for
each node. Paired samples from a patient are coloured according to the legend depicted on the bottom left corner. The x-axis represents the
years between 2001 and 2011
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distances (Additional file 7: Figure S4). In contrast, the
two 2014 hypermutator isolates from patient 37 that
are closest to AUS951 (AUS965 and AUS966), differ from
the 2007 isolate by 335 SNPs or 582 SNPs, respectively.
This observation reveals the relative impact of hypermuta-
tion on a within-host population over a 7-year time span
(Additional file 7: Figure S4), consistent with the previous
report of a ~ 40-fold higher mutation rate amongst hyper-
mutable P. aeruginosa in long-term CF infections [47].
The minimal spanning tree reveals a maximum of 74 core
SNPs separating the most divergent, non-hypermutator
isolates, (AUS941 [Patient 27; 2011] and AUS948 [Patient
40; 2011]) isolates (Additional file 7: Figure S4). The closest
sequential within-patient isolates (AUS956 and AUS957
from patient 41) differed by only two core SNPs demon-
strating a remarkably high degree of genome stability over a
4-year period (Additional file 7: Figure S4). Within-patient
isolates from patients 41 (AUS956 and AUS957) and 28
(AUS935 and AUS936) also grouped together with high
bootstrap support on the ML phylogeny, which is con-
sistent with continuous M3L7 infection across the two
sampling time-points (Additional file 6: Figure S3 and
Additional file 7: Figure S4). Our analyses also revealed
that a very close relationship existed between the early
and late isolates from patients 30 (AUS944 and AUS945, 9
SNPs) and 31 (AUS953 and AUS954, 13 SNPs), which
could also be due to continuous infection of the same
strain (Additional file 6: Figure S4). Although these four
isolates are grouped together with high bootstrap support
(Additional file 6: Figure S3), pairwise SNP comparisons
reveals only two core genome SNP differences between
the 2007 isolates from patients 30 and 31 (AUS944 and
AUS953, respectively) (Additional file 7: Figure S4).
Notably, the hypothesis of cross-infection between these
two patients (or from a common source) is supported by
the finding that both patients were admitted to the same
inpatient ward, at the same time, approximately 6 months
prior to their first positive M3L7 culture (Additional
file 4: Table S2).
Based on the Maximum-Likelihood phylogeny, the
isolates from patient 39 do not cluster closely (Additional
file 6: Figure S3). In fact, AUS947 [patient 39; 2011] is
most closely related to AUS961 [patient 37: 2014] and is
more closely related to AUS951 [patient 37; 2007] than
the earlier 2007 isolate from patient 39 (AUS946)
(Additional file 7: Figure S4). This indicates the possibility
of multiple M3L7 cross-infection events as has been
suggested for other shared strains [48], which may occur
via the airborne route or during socialisation between
patients [49, 50]. Pairwise SNP comparisons between
M3L7 isolates also shows a possible transmission pathway
with isolates AUS946 [patient 39; 2007] and AUS944
[patient 30, 2008] being the most likely source of cross-
infections (Additional file 7: Figure S4).
AUS22 (an M3L7 isolate sequenced as part of a different
study) and AUS943 were both isolated from patient 32 just
6 days apart in 2007. However, these two isolates were
more closely related to isolates from other patients than to
each other (Additional file 6: Figure S3). Given that only
one isolate per sputum sample was analysed, it is unclear
if this represents co-existence of multiple related sub-
lineages within the chronically infected lungs as we and
others have previously shown [5, 7, 17, 47, 48, 51] or if
this is also suggestive of direct or indirect cross-infection
between those patients. These possibilities are not mutu-
ally exclusive.
When analysed together with 11 previously published
isolates isolated from a single individual (Patient 37 in
this study) during an episode of acute pulmonary exacer-
bation over 3 months [17], M3L7 isolates from patient
36 (AUS948; 2007) and patient 40 (AUS949; 2011) were
found to cluster with the the non-hypermutator isolates
from Patient 37 (Additional file 6: Figure S3 and Additional
file 7: Figure S4). Interestingly, both hypermutator isolates
in patient 38 are more closely related to AUS951 [patient
37; 2007] than to each other, suggesting transmission via a
route common to patients 36, 37 and 40, followed by the
independent acquisition of mutS mutations. These findings
highlight that short-term within-patient diversity of
shared strains during chronic infection needs to be
considered in light of the P. aeruginosa lung diversity
of the local CF population as a whole.
The resolution of WGS data of multiple isolates from
individual patients within samples and longitudinally,
combined with social interaction data will enable future
studies to fully characterise long-term within-patient
M3L7 diversity and evolution and distinguish between
continuous infection or recent acquisition of M3L7 var-
iants amongst the CF population [14].
M3L7 is characterised by an accumulation of
non-synonymous mutations in critical pathways
Clonal lineages are expected to accumulate mutations
that enable adaptation of the bacterium to a specific
environmental niche of a human host [8]. A total of 44
shared SNPs and nine shared indels were acquired after
divergence of the M3L7 sub-lineage from all other
AUST-02 isolates of the M2 and M3 clades. Thirty-five
SNPs were non-synonymous (80%), resulting in a change
of the amino acid sequence including two premature stop
codons (Additional file 8: Table S4). Four indels produced
in-frame mutations, whilst five indels caused a shift in the
reading frame (Additional file 8: Table S4). The full list of
SNPs and indels found across M3L7 isolates can be found
in (Additional file 9: Table S5).
Genes containing non-synonymous SNPs and indels
exclusive to the M3L7 sub-lineage (n = 43) were subse-
quently categorised according to PseudoCAP (P. aeruginosa
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community annotation project) functions (Fig. 3) [52].
Fifteen genes were annotated with at least two functional
categories and nine genes were part of regulatory networks
(Fig. 3), including key global regulators (e.g. rpoN, mexT),
which might impact multiple processes [53]. Approxi-
mately 50% of the non-synonymous mutations occurred in
genes that encode proteins associated with virulence (e.g.
PilR involved in surface attachment and twitching motility
[54, 55]; MigA involved in swarming [56]; ZnuA in zinc
homeostasis [57]; PchD for iron acquisition [58]) or anti-
biotic resistance mechanisms (e.g. OprD: carbapenem
resistance [59]; GyrB: fluoroquinolone resistance [60]; FtsI,
Mpl: β-lactam resistance [61, 62]; PmrB, ColS: polymyxin
resistance [63, 64]; MexA, MexS, MexT: multi-drug efflux
pumps [65–68]). The mutations found in genes correlated
with antibiotic resistance were also identified in M3L7 iso-
lates collected in 2014 [17] and might help explain the
increased resistance to anti-pseudomonal antibiotics, in-
cluding meropenem, ceftazidime, ticarcillin-clavulanate,
aztreonam, ciprofloxacin and colistin, compared to other
AUST-02 subtypes, as described previously [16]. We did
not find any acquired antibiotic resistance genes in the
M3 clade isolates. Altogether this analysis suggests that
the M3L7 sub-lineage is characterised by mutations in
genes that might have aided adaptation to the CF airways
prior to dissemination in the CF population [4, 8, 47, 69].
Genomic variation due to large deletions
The draft genomes that comprise the M3L7 sub-lineage
ranged in size from 6.15 to 6.25 Mbp, whereas the M3L1
isolate (AUS970) genome was substantially smaller (6.05
Mbp). All genomes within the M3 clade had an average
GC content of 66.5%. Genome reduction is a typical evo-
lutionary process that occurs during adaptation [70];
therefore, large genomic variations (> 10 kb) were com-
pared between the AUST-02 isolates.
Major differences in genome size were not due to hori-
zontal gene transfer but attributed to several deletion events,
summarised in Table 1. For example, one M3L7 isolate
(AUS947; Patient 39; 2011) lost a large 93 Kbp region
encoding a number of virulence genes including exoY (a
T3SS secreted toxin), a three-part hydrogen cyanide biosyn-
thesis operon, hcnABC and part of the cupA1-A5 chaperone
usher fimbrae operon (Table 1). Deletions of varying sizes
encompassing exoY and hcnABC (of the same region) were
also missing in three other isolates within the M3 clade
(AUS853; [Patient 45; 2007]; AUS854 [Patient 44; 2007];
AUS970 [Patient 43; 2007]) suggesting that there was a
selective pressure to lose the functionality of genes encoded
at this position.
A 40 Kbp putative prophage was present in five
AUST-02 isolates from Perth (AUS15 [Patient 18; 2008];
AUS874 [Patient 22; 2008]; AUS17 [Patient 17; 2008];
AUS876 [Patient 21; 2008]; AUS877 [Patient 20; 2008])
and one isolate from Brisbane (AUS24; [Patient 16; 2007])
of the M2 clade. This prophage is present in nearly all
M3L7 genomes (absent in AUS958 [Patient 29; 2011]) and
a previous study also observed the presence of the pro-
phage in 9/11 M3L7 isolates collected in 2014 [17]. There-
fore, it is most likely that this prophage was present in the
last common ancestor of the M3L7 sub-lineage and was
vertically inherited. The prophage is inserted immediately
adjacent to the mutS gene and a search of the putative
prophage sequence using the PhaST webtool predicts a
complete prophage that is only 9% identical to the P. aeru-
ginosa F10 phage [37]. The prophage is flanked by an
18 bp att sequence (TCTCTCAGCACACGCC) that
delineates the deletion in AUS958.
Conclusions
The persistence of the AUST-02 shared strain in the CF
population in Australia has led to the emergence of a
monophyletic sub-lineage (M3L7) that is distinct from
Fig. 3 Genes (n= 43) with non-synonymous SNPs and indels that characterise the M3L7 sub-lineage. The black squares indicate the PseudoCAP function
of the gene. See Additional file 8: Table S4 for detailed information of the specific mutations. *Candidate pathoadaptive genes identified previously [8]
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the M2 sub-lineage of AUST-02. Our WGS analysis
demonstrated that M3L7 strains are characterised by
mutations in genes that are likely to affect antibiotic resist-
ance and virulence phenotypes. The rapid dissemination
of this clinically important sub-type is most likely due to a
combination of adaptation to the CF airway microenviron-
ment and transmission between people attending the same
CF centre. This work provides a framework for future
efforts in real-time genomic surveillance to monitor the
transmission and pathogenicity of AUST-02 amongst
the Australian CF population and to detect newly emer-
gent shared strains. Further genomic investigations are
required on multiple intra-sample isolates of this sub-type
to decipher potential mechanisms which facilitates its
epidemiological success.
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